Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05134480 · ClinicalTrials.gov registry record · NA
Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss
A NA study, sponsored by Case Western Reserve University.
- Completed
- Registry status
- NA
- Development phase
- 1,097
- Enrollment target
NCT05134480: Completed NA study, sponsored by Case Western Reserve University.
NCT05134480 is a NA study that has completed, run by Case Western Reserve University. The registered enrollment target is 1,097 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05134480, a NA study, has completed, sponsored by Case Western Reserve University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,097 participants
- Enrollment target
Study Summary
This double-masked multi-center trial will evaluate the association of diabetes in the cornea donor with transplant success and loss of endothelial cells through 1 year following Descemet membrane endothelial keratoplasty (DMEK). Study eyes are assigned to receive either a cornea from a donor without diabetes or a cornea from a donor with diabetes.
Primary Outcome
Graft failure is defined as the occurrence of one of the following: a graft which requires replacement for any reason or the recipient cornea remains cloudy after surgery without clearing for 8 weeks or longer
Interventions
- PROCEDURE Descemet membrane endothelial keratoplasty
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,097 participants |
| Start Date | 2022-01-21 |
| Est. Completion | 2025-09-15 |
| Phase | NA |
What the finished NCT05134480 record still lists
NCT05134480 is an interventional study that assigns participants to a tested intervention. Its 1,097 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 1 intervention - of which Descemet membrane endothelial keratoplasty is the first listed.
NCT05134480 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05134480 about?
NCT05134480 is a clinical study titled "Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss". This double-masked multi-center trial will evaluate the association of diabetes in the cornea donor with transplant success and loss of endothelial cells through 1 year following Descemet membrane endothelial keratoplasty (DMEK). Study eyes are assigned to receive either a cornea from a donor withou...
What is the current status of trial NCT05134480?
This trial is currently completed. It is a NA study. The enrollment target is 1,097 participants. The study started on 2022-01-21. Estimated completion is 2025-09-15.
What interventions are being tested in trial NCT05134480?
The interventions under investigation include: Descemet membrane endothelial keratoplasty (PROCEDURE).
Who is sponsoring clinical trial NCT05134480?
This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05134480's enrollment target sits among peer trials
1,097 95th of 2000 higher than 1,906 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191744 · 1,095 participants · Phase 3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI